64 related articles for article (PubMed ID: 26145714)
1. Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation.
Abu Hassan SO; Petersen PH; Lund F; Nielsen DL; Tuxen MK; Sölétormos G
Biomark Med; 2015; 9(9):911-22. PubMed ID: 26145714
[TBL] [Abstract][Full Text] [Related]
2. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
3. Criteria to interpret cancer biomarker increments crossing the recommended cut-off compared in a simulation model focusing on false positive signals and tumour detection time.
Lund F; Petersen PH; Pedersen MF; Abu Hassan SO; Sölétormos G
Clin Chim Acta; 2014 Apr; 431():192-7. PubMed ID: 24508631
[TBL] [Abstract][Full Text] [Related]
4. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
5. Interpretation of increments in serial tumour biomarker concentrations depends on the distance of the baseline concentration from the cut-off.
Petersen PH; Sölétormos G; Pedersen MF; Lund F
Clin Chem Lab Med; 2011 Feb; 49(2):303-10. PubMed ID: 21121866
[TBL] [Abstract][Full Text] [Related]
6. [CA-125 antigen].
Zakrzewska I
Postepy Hig Med Dosw; 2002; 56(1):29-38. PubMed ID: 11987487
[TBL] [Abstract][Full Text] [Related]
7. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
9. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up.
Tuxen MK; Sölétormos G; Dombernowsky P
Scand J Clin Lab Invest; 2002; 62(3):177-88. PubMed ID: 12088336
[TBL] [Abstract][Full Text] [Related]
10. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
11. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
[TBL] [Abstract][Full Text] [Related]
12. Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma.
Gadducci A; Menichetti A; Guiggi I; Notarnicola M; Cosio S
Anticancer Res; 2015 Feb; 35(2):1099-104. PubMed ID: 25667499
[TBL] [Abstract][Full Text] [Related]
13. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
14. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer.
Gemer O; Segal S; Kopmar A
Acta Obstet Gynecol Scand; 2001 Jun; 80(6):583-5. PubMed ID: 11380298
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
16. The role of CA125 in clinical practice.
Moss EL; Hollingworth J; Reynolds TM
J Clin Pathol; 2005 Mar; 58(3):308-12. PubMed ID: 15735166
[TBL] [Abstract][Full Text] [Related]
17. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
Han LY; Karavasilis V; Hagen Tv; Nicum S; Thomas K; Harrison M; Papadopoulos P; Blake P; Barton DP; Gore M; Kaye SB
Eur J Cancer; 2010 May; 46(8):1359-64. PubMed ID: 20303743
[TBL] [Abstract][Full Text] [Related]
18. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
Liu PY; Alberts DS; Monk BJ; Brady M; Moon J; Markman M
J Clin Oncol; 2007 Aug; 25(24):3615-20. PubMed ID: 17704410
[TBL] [Abstract][Full Text] [Related]
19. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
20. Significance of tumor marker determinations in the primary therapy of ovarian cancer.
Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2949-51. PubMed ID: 9329572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
